COLOT ITTELL IC 4556



Rox Factor VIII







Associated products

FACTOR VIII

CRYOcheck™ Abnormal 1 Reference Control

CRYOcheck™ Abnormal 2 Reference Control

CRYOcheck™ Reference Control Normal

vemal

Auxiliary reagents

Tris BSA

Informations

Factor VIII is a glycoprotein mainly synthesized by the liver.

It circulates in the plasma as bound to vWF which protects it from rapid proteolytic degradation.

It is activated by FXa or thrombin in FVIIIa which will complex with FIXa in the presence of phospholipids to activate FX in FXa.

A patient who is deficient in FVIII has hemophilia A.

Reference Presentation Number of tests 5-800070 Kit 2 x 100


Factor VIII colorimetric assay kit in human Factor VIII concentrates.

This kit for research use must not be used for the diagnosis or monitoring of patient treatment.

2 x 100 Stees. ittoring of patient treatment.

Components

- 2 vials of reagent 1 (lyophilisate of bovine FX, and fibrin polymerization inhibitor)
- 2 vials of reagent 2 (freeze-dried human FIXa and IIa, calcium chloride and phospholipids)
- 1 vial of FXa chromogenic substrate (6 mL)
- 1 vial of Tris-BSA dilution buffer (20 mL)



Method / Application

In the presence of Ca2 + and phospholipids, FX is activated to FXa by FIXa. This reaction is strongly stimulated by FVIII after activation to FVIIIa by thrombin.

Using optimal concentrations of Ca2 +, phospholipids, and excess FIXa, FX, and thrombin, the rate of FX activation is directly related to the amount of FVIII in the sample.

FXa hydrolyzes the chromogenic substrate, thus releasing the pNA chromophore group. The intensity of the color is proportional to the FVIII activity in the sample.

Characteristics

- Linearity: 0 2 IU / mL (0-200%)
- Detection limit 0.003 IU / mL (0.3%)
- FVIIIExcellent discrimination of FVIII activity
- Factor VIII deficient plasma not needed
- Reagent in accordance with the European Pharmacopoeia for the determination of FVIII
- Very stable on analyzers.

